NCT06602037View on ClinicalTrials.gov

ImmunoPET Imaging of Pancreatic Cancer

NARecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 13, 2024

Primary Completion Date

June 16, 2027

Study Completion Date

June 16, 2027

Conditions
Neoplasms Pancreatic
Interventions
DIAGNOSTIC_TEST

[89Zr]Zr-DFO-SHR1920

Enrolled pancreatic cancer patients will receive a single dose (1-3mCi) of \[89Zr\]Zr-DFO-SHR1920 (total 1-2mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).

DIAGNOSTIC_TEST

[18F]F-RESCA-3A12

Enrolled pancreatic cancer patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-3A12. ImmunoPET/CT imaging will be acquired 1h after \[18F\]F-RESCA-3A12 injection.

DIAGNOSTIC_TEST

[68Ga]Ga-NOTA-3A12

Enrolled pancreatic cancer patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-3A12. ImmunoPET/CT imaging will be acquired 1h after \[68Ga\]Ga-NOTA-3A12 injection.

Trial Locations (1)

200127

RECRUITING

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER